- Patients treated with a tumor necrosis factor-alpha inhibitor are more likely to develop extrapulmonary tuberculosis
-
Lee SO
- KMID: 1501769
- Korean J Intern Med.
- 2013 Mar;28(2):159-161.
- doi: 10.3904/kjim.2013.28.2.159
No abstract available. -
- CITED
-
- Close
- SHARE
-
- Close
- A Case of Tuberculous Arthritis Following the Use of Etanercept
-
Choi SW, Ahn JJ, Hwang YT, Koh SH, Cho SD
- KMID: 1776672
- Korean J Intern Med.
- 2009 Dec;24(4):397-401.
- doi: 10.3904/kjim.2009.24.4.397
Etanercept is a tumor necrosis factor (TNF) inhibitor that has been used for the treatment of chronic inflammatory diseases including rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis. Because of its... -
- CITED
-
- Close
- SHARE
-
- Close
- Clinical characteristics and treatment responses of patients who developed tuberculosis following use of a tumor necrosis factor-alpha inhibitor
-
Chung KB, Lee EY, Im JP, Han SK, Yim JJ
- KMID: 1501772
- Korean J Intern Med.
- 2013 Mar;28(2):174-179.
- doi: 10.3904/kjim.2013.28.2.174
BACKGROUND/AIMS: Individuals being treated with tumor necrosis factor (TNF)-alpha inhibitors are at increased risk of developing tuberculosis (TB). We determined the clinical characteristics and treatment response of patients who developed... -
- CITED
-
- Close
- SHARE
-
- Close
- Emerging Drugs in the Treatment of Inflammatory Bowel Disease: Beyond Anti-TNF-alpha
-
Kim KO, Jang BI
- KMID: 1026364
- Korean J Gastroenterol.
- 2011 Nov;58(5):235-244.
- doi: 10.4166/kjg.2011.58.5.235
Understanding of the pathophysiology of inflammatory bowel disease (IBD) is constantly evolving and, recently, a number of biologic agents have been developed. They selectively target specific molecule or pathways and... -
- CITED
-
- Close
- SHARE
-
- Close
- Safe Re-administration of Tumor Necrosis Factor-alpha (TNFalpha) Inhibitors in Patients with Rheumatoid Arthritis or Ankylosing Spondylitis Who Developed Active Tuberculosis on Previous Anti-TNFalpha Therapy
-
Suh YS, Kwok SK, Ju JH, Park KS, Park SH, Yoon CH
- KMID: 1796912
- J Korean Med Sci.
- 2014 Jan;29(1):38-42.
- doi: 10.3346/jkms.2014.29.1.38
There is no consensus on whether it is safe to re-administer tumor necrosis factor-alpha (TNFalpha) inhibitors in patients with rheumatoid arthritis (RA) or ankylosing spondylitis (AS) flared after withdrawal of... -
- CITED
-
- Close
- SHARE
-
- Close
- The Risk of Tuberculosis in Korean Patients with Inflammatory Bowel Disease Receiving Tumor Necrosis Factor-alpha Blockers
-
Byun JM, Lee CK, Rhee SY, Kim HJ, Kim JW, Shim JJ, Jang JY
- KMID: 2129648
- J Korean Med Sci.
- 2015 Feb;30(2):173-179.
- doi: 10.3346/jkms.2015.30.2.173
The aims of this study were to assess the risk of tuberculosis (TB) and the status of latent tuberculosis infection (LTBI) in Korean patients with inflammatory bowel disease (IBD) receiving... -
- CITED
-
- Close
- SHARE
-
- Close
- Anti-TNF-alpha Therapy for Ankylosing Spondylitis
-
Son JH, Cha SW
- KMID: 1110346
- Clin Orthop Surg.
- 2010 Mar;2(1):28-33.
- doi: 10.4055/cios.2010.2.1.28
BACKGROUND: This review evaluated the safety and efficacy of etanercept in patients with ankylosing spondylitis (AS). METHODS: Of 59 patients with AS, this study reviewed 11 patients who were refractory to... -
- CITED
-
- Close
- SHARE
-
- Close
- Diagnosis and Treatment of Latent Tuberculosis Infection in Arthritis Patients Treated with Tumor Necrosis Factor Antagonists in Korea
-
Yun JW, Lim SY, Suh GY, Chung MP, Kim H, Kwon OJ, Cha HS, Koh EM, Koh WJ
- KMID: 1713280
- J Korean Med Sci.
- 2007 Oct;22(5):779-783.
- doi: 10.3346/jkms.2007.22.5.779
Tumor necrosis factor (TNF) is essential for host defense against Mycobacterium tuberculosis, and the risk of reactivation of latent tuberculosis infection (LTBI) increases with anti-TNF therapy. This study estimated the... -
- CITED
-
- Close
- SHARE
-
- Close
- Patients with Arthritis Undergoing Surgery: How Should We Manage Tumour Necrosis Factor Blocking Agents Perioperatively?: A Systematic Literature Review
-
Pieringer , Danninger , Tzaribachev N, Bohler N, Pohanka E, Herold M
- KMID: 1776947
- Yonsei Med J.
- 2013 Jan;54(1):253-257.
- doi: 10.3349/ymj.2013.54.1.253
We systematically reviewed the literature on the infectious risk in patients treated with tumour necrosis factor blocking agents (TNF-BA) undergoing surgery: we searched the Medline (PubMed) and the online archive... -
- CITED
-
- Close
- SHARE
-
- Close
- The Effect of TNF-α Blocker HL036337 and Its Best Concentration to Inhibit Dry Eye Inflammation
-
Choi W, Noh H, Yeo A, Jang H, Ahn HK, Song YJ, Lee HK
- KMID: 2373991
- Korean J Ophthalmol.
- 2016 Aug;30(4):302-308.
- doi: 10.3341/kjo.2016.30.4.302
PURPOSE: Dry eye syndrome is commonly thought of as an inflammatory disease, and we have previously presented data showing the effectiveness of topical TNF-α blocker agents for the treatment of... -
- CITED
-
- Close
- SHARE
-
- Close
- Repression of TNF-alpha-induced IL-8 expression by the glucocorticoid receptor-beta involves inhibition of histone H4 acetylation
-
Kim SH, Kim DH, Lavender P, Seo JH, Kim YS, Park JS, Kwak SJ, Jee YK
- KMID: 1123803
- Exp Mol Med.
- 2009 May;41(5):297-306.
- doi: 10.3858/emm.2009.41.5.033
Increased expression of a number of proinflammatory genes, including IL-8, is associated with inflammatory conditions such as asthma. Glucocorticoid receptor (GR)beta, one of the GR isoforms, has been suggested to... -
- CITED
-
- Close
- SHARE
-
- Close
- Prevention of TNF-induced necrotic cell death by rottlerin through a Nox1 NADPH oxidase
-
Byun HS, Won M, Park KA, Kim YR, Choi BL, Lee H, Hong JH, Piao L, Park J, Kim JM, Kweon GR, Kang SH, Han J, Hur GM
- KMID: 1052941
- Exp Mol Med.
- 2008 Apr;40(2):186-195.
- doi: 10.3858/emm.2008.40.2.186
Previous studies have demonstrated that rottlerin, a specific PKCdelta inhibitor, potentiates death receptor- mediated apoptosis through a cytochrome c-dependent or -independent pathway. However, its ability to regulate necrotic cell death,... -
- CITED
-
- Close
- SHARE
-
- Close
- Mortality in patients with rheumatoid arthritis-associated interstitial lung disease treated with an anti-tumor necrosis factor agent
-
Koo BS, Hong S, Kim YJ, Kim YG, Lee CK, Yoo B
- KMID: 2129670
- Korean J Intern Med.
- 2015 Jan;30(1):104-109.
- doi: 10.3904/kjim.2015.30.1.104
BACKGROUND/AIMS: To evaluate the impact on mortality of anti-tumor necrosis factor (anti-TNF) treatment of rheumatoid arthritis-associated interstitial lung disease (RA-ILD). METHODS: We retrospectively reviewed the medical records of 100 RA-ILD patients... -
- CITED
-
- Close
- SHARE
-
- Close
- Factors Contributing to the Preference of Korean Patients with Crohn's Disease When Selecting an Anti-Tumor Necrosis Factor Agent (CHOICE Study)
-
Kim ES, Kim KO, Jang BI, Lee CK, Kim HJ, Lee KM, Kim YS, Eun CS, Jung SA, Yang SK, Lee J, Kim TO, Jung Y, Seo GS, Yoon SM, the IBD Study Group of the Korean Association for the Study of the Intestinal Diseases (KASID)
- KMID: 2411966
- Gut Liver.
- 2016 May;10(3):391-398.
- doi: 10.5009/gnl15126
BACKGROUND/AIMS: Two comparable anti-tumor necrosis factor (TNF) agents with different routes of administration (intravenous [iv] infliximab [IFX] vs subcutaneous [sc] adalimumab [ADA]) are available for patients with Crohn's disease (CD)... -
- CITED
-
- Close
- SHARE
-
- Close
